
    
      The Phase II study is to establish the maximum tolerated dose of i.v. IOP Injection
      (MPB-1514) in Part 1 and to evaluate the safety and efficacy of the maximally tolerated dose
      of IOP Injection with different infusions schemes in Part 2.
    
  